Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75718
UPID:
CRTAP_HUMAN
Alternative names:
-
Alternative UPACC:
O75718; B2RBL6
Background:
Cartilage-associated protein plays a pivotal role in the structural integrity of connective tissues, primarily through its necessary function in the 3-hydroxylation of fibrillar collagen prolyl residues. This enzymatic activity is crucial for the proper formation and maintenance of collagen, a key component of the extracellular matrix.
Therapeutic significance:
The protein's involvement in Osteogenesis imperfecta 7, a severe connective tissue disorder, underscores its potential as a therapeutic target. Effective modulation of Cartilage-associated protein activity could lead to breakthrough treatments for patients suffering from this debilitating condition, characterized by bone fragility and susceptibility to fractures.